Biofrontera Inc.
Close on Oct 19, 2026
- Market cap
- $10.41M
- P/E (TTM)
- –
- Dividend yield
- –
About Biofrontera
Pharmaceutical Preparations, SIC 2834
Biofrontera Inc. is a biopharmaceutical company that develops, manufactures, and commercializes pharmaceutical treatments for dermatological conditions, focusing on photodynamic therapy. Its primary product line comprises Ameluz, a prescription drug, and the RhodoLED series of illumination lamps, including BF-RhodoLED and RhodoLED XL. Together, these products are used to treat actinic keratosis, a pre-cancerous skin condition, on the face and scalp. In addition to commercializing these products, the company conducts research and development focused on expanding approved indications. Biofrontera sells its products directly to dermatology offices and groups using a buy-and-bill distribution model.
The company operates primarily in the United States and has an international footprint that includes clinical research activities. As of late 2025, its workforce totals 92 employees, with 75 located in the United States and 19 based in Germany. Biofrontera Inc. maintains its principal executive offices and corporate headquarters in Woburn, Massachusetts.
Summary of the business section of Biofrontera's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Biofrontera Inc.
- Founded
- 2015
- Headquarters
- Woburn, MA
- Address
- 120 Presidential Way,, Suite 330 01801
- Phone
- (781) 245-1325
- Website
- biofrontera-us.com
- Employees
- 92, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum llp, Morristown, New Jersey
Stock & identifiers
- Ticker
- BFRI
- Other tickers
- BFRIW
- Exchange
- Nasdaq
- IPO date
- Nov 1, 2021
- Shares outstanding
- 15M, Aug 11, 2026
- Public float
- $6.90M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-20 reverse, Aug 11, 2023; 1-for-20 reverse, Jul 5, 2023
- SEC CIK
- 1858685
- CUSIP
- 09077D209
- ISIN
- US09077D2099
- LEI
- 984500444S8BE1EF0179
- EIN
- 47-3765675
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Hermann Luebbert | CEO & Chairman, Director | 352,711 |
| Eugene Frederick Leffler | Chief Financial Officer | 206,250 |
| George Patrick Jones | Chief Commercial Officer | – |
| Beth J. Hoffman | Director | – |
| Kevin Daniel Weber | Director | – |
| Heikki Lanckriet | Director | – |
| John J. Borer Iii | Director | – |
| la Huerta Martinez Maria del Pilar de | Director | 400,000 |
| AG Biofrontera | Director | 400,000 |
Employees
Headcount reported in annual reports
“of December 31, 2025, the Company had a total of 92 employees comprised of 75 employees (72 full-time and three part-time) in”
Corporate history
Events identified from SEC filings